The utility of serum N-ERC/mesothelin as a biomarker of ovarian carcinoma
- Authors:
- Harumi Saeki
- Akane Hashizume
- Hiroshi Izumi
- Fujihiko Suzuki
- Kazuhisa Ishi
- Michio Nojima
- Masahiro Maeda
- Okio Hino
View Affiliations
Affiliations: Department of Diagnostic Pathology, Juntendo University Urayasu Hospital, Chiba, Japan, Department of Obstetrics and Gynecology, Juntendo University Urayasu Hospital, Chiba, Japan, Immuno-Biological Laboratories Co., Ltd., Gunma, Japan, Department of Pathology and Oncology, Juntendo University, School of Medicine, Tokyo, Japan
- Published online on: July 11, 2012 https://doi.org/10.3892/ol.2012.796
-
Pages:
637-641
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Ovarian carcinoma has been difficult to diagnose at an early stage. Recently, it has been recognized that the measurement of blood N-ERC/mesothelin levels aids early detection in and postoperative therapeutic monitoring of patients with mesothelioma, who have been exposed to asbestos. ERC/mesothelin has also been reported to be expressed in ovarian carcinoma. We determined serum N-ERC/mesothelin levels in patients with ovarian carcinoma using an enzyme‑linked immunosorbent assay (ELISA). In addition, we immunohistochemically evaluated surgically resected specimens for C-ERC/mesothelin expression. As a result, of the 32 patients with ovarian tumors (18 carcinoma, 2 borderline tumors), one patient with serous adenocarcinoma showed increased N-ERC/mesothelin levels. Immunohistochemically, of the 20 ovarian tumor (carcinoma and borderline tumor) specimens evaluated for serum N-ERC/mesothelin, 9 (45.0%) were positive for C-ERC/mesothelin. The C-ERC/mesothelin-positive specimens were found to be serous and clear cell adenocarcinomas. If serum N-ERC/mesothelin, which is considered useful for early detection in and therapeutic monitoring of patients with mesothelioma, may also be used for ovarian carcinoma monitoring, it may be a valuable serum tumor marker for the early detection of ovarian carcinoma.
View References
|
1.
|
K ShiomiH MiyamotoT SegawaNovel ELISA
system for detection of N-ERC/mesothelin in the sera of
mesothelioma patientsCancer
Sci97928932200610.1111/j.1349-7006.2006.00246.x16776777
|
|
2.
|
K ShiomiY HagiwaraK SonoueSensitive and
specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin
increases its potential as a useful serum tumor marker for
mesotheliomaClin Cancer
Res1414311437200810.1158/1078-0432.CCR-07-161318316566
|
|
3.
|
K ImashimizuK ShiomiM MaedaFeasibility of
large-scale screening using N-ERC/mesothelin levels in the blood
for the early diagnosis of malignant mesotheliomaExp Ther
Med2409411201122977518
|
|
4.
|
M HoR HassanJ ZhangQ WangM OndaT BeraI
PastanHumoral immune response to mesothelin in mesothelioma and
ovarian cancer patientsClin Cancer
Res1138143820200510.1158/1078-0432.CCR-04-230415897581
|
|
5.
|
O HinoE KobayashiM NishizawaRenal
carcinogenesis in the Eker ratJ Cancer Res Clin
Oncol121602605199510.1007/BF011977777559744
|
|
6.
|
R HassanT BeraI PastanMesothelin: a new
target for immunotherapyClin Cancer
Res1039373942200410.1158/1078-0432.CCR-03-080115217923
|
|
7.
|
R HassanAT RemaleyML SampsonDetection and
quantitation of serum mesothelin, a tumor marker for patients with
mesothelioma and ovarian cancerClin Cancer
Res12447453200610.1158/1078-0432.CCR-05-147716428485
|
|
8.
|
K IshikawaT SegawaY HagiwaraM MaedaM AbeO
HinoEstablishment of novel mAb to human ERC/mesothelin useful for
study and diagnosis of ERC/mesothelin-expressing cancersPathol
Int59161166200910.1111/j.1440-1827.2009.02344.x19261093
|
|
9.
|
RJ KurmanIM ShinThe origin and
pathogenesis of epithelial ovarian cancer: a proposed unifying
theoryAm J Surg
Pathol34433443201010.1097/PAS.0b013e3181cf3d7920154587
|
|
10.
|
RE ScullyJF Barlow“Mesonephroma” of ovary.
Tumor of Müllerian nature related to the endometrioid
carcinomaCancer20140514171967
|
|
11.
|
I HellstromJ RaycraftS KananNY SardesaiT
VerchY YangKE HellstromMesothelin variant 1 is released from tumor
cells as a diagnostic markerCancer Epidemiol Biomarker
Prev1510141020200610.1158/1055-9965.EPI-05-033416702385
|
